Project Updates

Credit; Vaxxas

Location: Brisbane, Australia 
Project type: Biomedical Manufacturing facility 
Area: 5,500m² (60,000ft²)

Vaxxas opened a new biomedical manufacturing facility in Brisbane, Australia, in June 2023. The facility is designed to support the scale-up of Vaxxas’ needle-free vaccine technology platform named high-density microarray patch (HD-MAP) for late-stage clinical trials and commercial products.

Credit; Thermo Fisher Scientific

Location: Lengnau, Switzerland 
Project type: Biomanufacturing facility 
Area: 1.5 million square feet

Thermo Fisher Scientific developed a new biologics manufacturing facility in Lengnau, in the Swiss canton of Bern, to improve its pharmaceutical services capacity and manufacturing capabilities to meet the growing demand for biologic therapies.

Credit; PictureDesignSwiss/Shutterstck.com

Location:  Luterbach, Solothurn, Switzerland 
Project type: Biologics manufacturing facility 
Investment: CHF1.5bn ($1.5bn)

Biogen has developed a biologics manufacturing facility in Luterbach near Solothurn, Switzerland. The state-of-the-art facility aims to meet the increasing demand for high-quality protein-based drugs or biologics that target severe neurodegenerative, haematological or autoimmune diseases.